AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

Company Overview

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.49 to $0.86
• 52-Week Range: N/A
• Volume: 243,500 shs
• Average Volume: 137,683 shs
• Market Capitalization: $14.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACRX Stock Analysis - Frequently Asked Questions

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings data on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.40). The specialty pharmaceutical company earned $1.86 million during the quarter, compared to the consensus estimate of $1.20 million.

When did AcelRx Pharmaceuticals' stock split?

Shares of AcelRx Pharmaceuticals reverse split on the morning of Wednesday, October 26th 2022.The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ACRX
• CIK: 1427925
• Web: www.acelrx.com
• Phone: (650) 216-3500
• Fax: 650-216-6500
• Employees: 19
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $47.76 million
• Net Margins: N/A
• Pretax Margin: -3,711.25%
• Return on Equity: -81.54%
• Return on Assets: -46.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $1.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 16,950,000
• Free Float: 16,443,000
• Market Cap: $14.58 million
• Optionable: Optionable
• Beta: 0.52